ArticleJournal of advanced research2026
Acidic tumor microenvironment-modulated nanoparticle potentiates gastric cancer photoimmunotherapy.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review).Oncology reports · 2026Review
- Targeting the NAT1-ENO1-Lactate Axis Destabilizes PD-L1 to Reinvigorate Antitumor Immunity in Colorectal Cancer.MedComm · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Virus-based IFNγ gene delivery and photodynamic therapy cooperate to remodel the tumor microenvironment and suppress breast cancer.Molecular therapy. Oncology · 2026Article
- Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review).Oncology letters · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmunotherapy, especially anti-PD-1 antibodies (α-PD-1), has revolutionized the landscape of cancer treatment. However, the response rate of α-PD-1 for Gastric Cancer (GC) remains relatively low. The acidic immunosuppressive Tumor Microenvironment (TME) greatly hinders the efficacy of α-PD-1. Thus, therapeutic strategies targeting the acidic TME in GC are highly desired.
objectivesThis study aimed to investigate the effect of FX-11@PEG-Ce6 on the therapeutic efficacy of photoimmunotherapy for gastric cancer.
methodsWe developed FX-11 encapsulated with PEG-Ce6 nanoparticles (FX-11@PEG-Ce6) for GC photoimmunotherapy. The morphology was observed by transmission electron microscopy. Flow cytometry was performed to detect the maturation level of dendritic cells and the levels of TNF-α, IFN-γ, and granzyme B in CD8
resultsAs a type of nanoplatform, FX-11@PEG-Ce6 demonstrated satisfactory cellular uptake and tumor targeting ability. FX-11@PEG-Ce6 provoked significant immunogenic cell death response. Meanwhile, the results of flow cytometry showed that FX-11@PEG-Ce6 facilitated the maturation of dendritic cells and augmented the secretion of T-cell cytokines. Through the detection of the pH of the cell culture medium, it was revealed that FX-11@PEG-Ce6 could alleviate the acidity of the TME, thereby restoring the function of T cells and enhancing the anti-tumor activity of CD8
conclusionOur results revealed that the combination of FX-11@PEG-Ce6-based photodynamic therapy and immunotherapy could achieve a synergistic antitumor effect with excellent biosafety, presenting great therapeutic potential for enhanced photoimmunotherapy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.